12Jun/18

FDA Approves Genentech’s Rituxan For Pemphigus Vulgaris

The U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painfulRead More…